Longeveron (LGVN) Equity Average (2022 - 2026)
Longeveron (LGVN) recorded quarterly Equity Average of $10.9 million in Q1 2026, up 38.75% quarter-over-quarter from $7.8 million in Q4 2025, and down 44.42% on a YoY basis from $19.5 million in Q1 2025.
Longeveron (LGVN) Equity Average (2022 - 2026) Analysis & Trends
Longeveron's Equity Average history runs 5 years deep, the most recent figure standing at $10.9 million for Q1 2026.
- In Q1 2026, Equity Average fell 44.42% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (down 44.42% YoY), while the FY2025 annual figure was $13.8 million, down 3.72% from the prior year.
- Equity Average was $10.9 million for Q1 2026 at Longeveron, up from $7.8 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $35.9 million in Q1 2022 to a low of $4.9 million in Q1 2024.
- Historically, Equity Average has averaged $16.9 million across 5 years, with a median of $14.9 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Equity Average sank 73.43% in 2024, then jumped 299.15% in 2025.
- A 5-year view of Equity Average shows it stood at $22.6 million in 2022, then slumped by 70.36% to $6.7 million in 2023, then surged by 255.3% to $23.8 million in 2024, then tumbled by 67.08% to $7.8 million in 2025, then jumped by 38.75% to $10.9 million in 2026.
- The last three Equity Average figures came in at $10.9 million (Q1 2026), $7.8 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 10.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.85 Mn |
| Dec 31, 2025 | 7.82 Mn |
| Sep 30, 2025 | 11.31 Mn |
| Jun 30, 2025 | 14.91 Mn |
| Mar 31, 2025 | 19.52 Mn |
| Dec 31, 2024 | 23.76 Mn |
| Sep 30, 2024 | 20.27 Mn |
| Jun 30, 2024 | 8.98 Mn |
| Mar 31, 2024 | 4.89 Mn |
| Dec 31, 2023 | 6.69 Mn |
| Sep 30, 2023 | 8.95 Mn |
| Jun 30, 2023 | 13.79 Mn |
| Mar 31, 2023 | 18.41 Mn |
| Dec 31, 2022 | 22.56 Mn |
| Sep 30, 2022 | 27.00 Mn |
| Jun 30, 2022 | 31.84 Mn |
| Mar 31, 2022 | 35.88 Mn |